Not Signed In - Cytokinetics Reports Data For Ispinesib In Recurrent And/or Metastatic Head And Neck Squamous Cell Carcinoma
Tue, 03 Oct 2006 07:00 AM EST
... Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from a planned interim analysis following Stage 1 of a two-stage Phase II clinical trial of ispinesib administered as monotherapy in the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC). [click link for full article] ...
Related Topics
- Skin Cancer
- Squamous Neck Cancer with Occult Primary, Metastatic
- Metastatic Squamous Neck Cancer with Occult Primary
- Head Injury
- Squamous Cell Carcinoma, see Skin Cancer
- Data & Statistics
- Small Cell Lung Cancer
- Data Analysis
- Head Lice
- National Data
- Metastatic Cancer
- Liver Cancer
- Merkel Cell Carcinoma
- Islet Cell Carcinoma
- Neck/Head Cancer
- Renal cell carcinoma
- Islet Cell Carcinoma (Pancreatic)
- Skin Carcinoma, Merkel Cell
- Islet Cell Carcinoma (Endocrine Pancreas)
- Basal Cell Carcinoma, see Skin Cancer
email this page
print this page
bookmark this page
feedback on this page
